

# Elacestrant (dihydrochloride)

Catalog No: tcsc6324



## Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1349723-93-8

**Formula:**

$C_{30}H_{40}Cl_2N_2O_2$

**Pathway:**

Others

**Target:**

Estrogen Receptor/ERR

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 17.6 mg/mL (33.11 mM; Need ultrasonic and warming)

**Alternative Names:**

RAD1901 dihydrochloride

### Observed Molecular Weight:

531.56


### Product Description

Elacestrant dihydrochloride (RAD1901 dihydrochloride) is a selective and orally available estrogen receptor (**ERR**) degrader with **IC<sub>50</sub>** values of 48 and 870 nM for ER $\alpha$  and ER $\beta$ , respectively.

IC50 & Target: IC50: 48 nM (ER $\alpha$ ), 870 nM (ER $\beta$ )<sup>[1]</sup>

**In Vitro:** RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation. RAD1901 treatment exhibits dose-dependent inhibition of ER $\alpha$  expression, with an EC<sub>50</sub> of 0.6 nM. Treatment of ER-positive MCF-7 cells with E2 results in a potent and dose-dependent increase in proliferation, with an EC<sub>50</sub> of 4 pM. Treatment of cells with RAD1901 in the presence of 10 pM E2 results in a dose-dependent decrease in proliferation, with an IC<sub>50</sub> value of 4.2 nM<sup>[1]</sup>.

**In Vivo:** RAD1901 produces a robust and profound inhibition of tumor growth in MCF-7 xenograft models. RAD1901-treated animals survived longer than those treated with either control or fulvestrant. RAD1901 preserves ovariectomy-induced bone loss and prevents the uterotrophic effects of E2<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!